Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Recruiting now · Phase 1
Conditions studied: Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Diffuse-large B-cell Lymphoma (DLBCL), Waldenstrom's Macroglobulinemia (WM)
In brief
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Key facts
- Study ID
- NCT06980116
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- People needed
- 85
- Starts
- 2025-03-31
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- LLC ARENSIA Exploratory Medicine — Tbilisi, Georgia (enrolling)
- IMSP Institute of Oncology, ARENSIA Exploratory Medicine — Chisinau, Moldova (enrolling)
- Hospital Beata Maria Ana — Madrid, Spain (enrolling)
- Hospital Fundación Jiménez Diaz — Madrid, Spain (enrolling)
- Hospital Universitario HM Sanchinarro — Madrid, Spain (enrolling)
- Clinica Universidad de Navarra — Pamplona, Spain (enrolling)
- Medical Center of LLC ARENSIA Exploratory Medicine — Kyiv, Ukraine (enrolling)
- St James's University Hospital — Leeds, United Kingdom (enrolling)
- University Hospitals Plymouth NHS Trust (Derriford Hospital) — Plymouth, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.